Identification of a novel HIV type 1 CRF01_AE cytotoxic T lymphocyte (CTL) epitope restricted by an HLA-Cw0602 allele and a novel HLA-A0206/peptide restriction

AIDS Research and Human Retroviruses

Volumn 22, Issue 12, 2006, Pages 1271-1282

  Kantakamalakul, Wannee ^a   De Souza, Mark ^b   Bejrachandra, Sasitorn ^c   Ampol, Silawun ^a   Cox, Josephine ^d   Sutthent, Ruengpung ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d US Military HIV Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; VIRUS ENVELOPE PROTEIN;

ARTICLE; CD8+ T LYMPHOCYTE; CLADISTICS; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; THAILAND;

CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HLA-A ANTIGENS; HLA-C ANTIGENS; HUMANS; INTERFERON TYPE II; SEQUENCE ANALYSIS, PROTEIN; THAILAND;

EID: 33846191162     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.1271     Document Type: Article

References (33)

1. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
2. Koup RA, Safrit JT, Cao Y, et al: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
3. McMichael AJ and Rowland-Jones SL: Cellular immune responses to HIV. Nature 2001;410:980-987.
4. Goulder PJ, Phillips RE, Colbert RA, et al.: Late escape from an immunodominant cytotoxic T-lymphocytes response associated with progression to AIDS. Nat Med 1997;3:212-217.
5. Klein M, van BC, Holwerda G, et al.: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
6. Koenig S, Conley AJ, Brewah YA, et al.: Transfer of HIV-1 specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995;1:330-336.
7. Garber DA, Silvestri G, and Feinberg MB: Prospects for an AIDS vaccine: Three big questions, no easy answers. Lancet Infect Dis 2004;4:397-413.
8. McMichael A and Hanke T: The quest for an AIDS vaccine; is the CD8+ T-cell approach feasible? Nat Immunol 2002;2:283-291.
9. Robinson H: New hope for an AIDS vaccine. Nat Rev Immunol 2002;2:239-250.
10. HIV Molecular Immunology Database 2005: HIV Sequence Database, Los Almos National Laboratory, Los Alamos, NM. http://www.hiv.lanl.gov/content/immunology/ index.html.
11. Janssens W, Buve A, and Nkengasong JN: The puzzle of HIV-1 subtypes in Africa. AIDS 1997;11:705-712.
12. Ruxrungtham K and Phanuphak P: Update on HIV/AIDS in Thailand. J Med Assoc Thai 2001;84(Suppl. 1):S1-17.
13. Weniger BG, Takebe Y, Ou CY, and Yamazaki S: The molecular epidemiology of HIV in Asia. AIDS 1994;8(Suppl. 2):S13-28.
14. Bond KB, Sriwanthana B, Hodge TW, et al.: An HLA-directed molecular and bioinformatics approach identifies new HLA-A11 HIV-1 subtype E cytotoxic T lymphocyte epitopes in HIV-1-infected Thais. AIDS Res Hum Retroviruses 2001;17:703-717.
15. W0304 alleles. J Virol 2002;76:4971-4986.
16. Dorrell L, Dong T, Ogg GS, et al.: Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J Virol 1999;73:1708-1714.
17. Fukada K, Tomiyama H, Wasi C, et al.: Cytotoxic T-cell recognition of HIV-1 cross-clade and clade-specific epitopes in HIV-1 infected Thai and Japanese patients. AIDS 2002;16:701-711.
18. Goulder PJ: Rapid characterization of HIV clade C-specific cytotoxic T lymphocyte responses in infected African children and adults. Ann NY Acad Sci 2000;918:330-345.
19. Mashishi T, Loubser S, Hide W, et al.: Conserved domains of subtype C nef from South African HIV type 1-infected individuals include cytotoxic T lymphocyte epitope-rich regions. AIDS Res Hum Retroviruses 2001;17:1681-1687.
20. Nitayaphan S, Pitisuttithum P, Karnasuta C, et al.: Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004;190: 702-706.
21. Paris R, Bejrachandra S, Karnasuta C, et al.: HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens 2004;64:251-256.
22. Sreepian A, Srisurapanon S, Horthongkham N, et al.: Conserved neutralizing epitopes of HIV type 1 CRF01_AE against primary isolates in long-term nonprogressors. AIDS Res Human Retroviruses 2004;20:531-542.
23. Kantakamalakul W, De Souza M, Karnasuta C, et al.: Enhanced sensitivity of detection of cytotoxic T lymphocyte responses to HIV type 1 proteins using an extended in vitro stimulation period for measuring effector function in volunteers enrolled in an ALVAC-HIV phase I/II prime boost vaccine trial in Thailand. AIDS Res Hum Retroviruses 2004;20:642-644.
24. Meidenbauer N, Harris DT, Spitler LE, and Whiteside TL: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000;43:88-100.
25. Schultes BC and Whiteside TL: Monitoring of immune responses to CA125 with an IFN-gamma ELISPOT assay. J Immunol Methods 2003;279:1-15.
26. Chandanayingyong D, Bejrachandra S, Kunachiwa W, et al.: HLA in Thai population. Mahidol J 2000;7:53-60.
27. Vejbaesya S, Eiermann TH, Suthipinititharm P, et al.: Serological and molecular analysis of HLA class I and II alleles in Thai patients with psoriasis vulgaris. Tissue Antigens 1998;52:389-392.
28. Falk K, Rotzschke O, Grahovac B, et al: Allele-specific peptide ligand motifs of HLA-C molecules. Proc Natl Acad Sci USA 1993;90:12005-12009.
29. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, and Sette A: Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 2001;62:1200-1216.
30. Sudo T, Kamikawaji N, Kimura A, et al.: Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol 1995;155:4749-4756.
31. Wilson CC, Kalams SA, Wilkes BM, et al.: Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA-A, B, and C molecules: Effected of viral variation on cytotoxic T-lymphocyte recognition. J Virol 1997;71:1256-1264.
32. Currier JR, Visawapoka U, Tovanabutra S, et al.: CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: Use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol 2006;7:8-24.
33. Vogel TU, Horton H, Fuller DH, et al.: Differences between T cell epitopes recognized after immunization and after infection. J Immunol 2002;169:4511-4521.